Latest Non Dilutive Funding News

Dimerix Limited (ASX: DXB) has inked its fifth regional licensing agreement with Everest Medicines, boosting potential milestone payments to A$1.9 billion and expanded its kidney disease pipeline through the acquisition of DMX-652. The Phase 3 ACTION3 trial for DMX-200 remains statistically robust, with funding secured to advance both clinical programs.

HITIQ Limited has fortified its financial position through a $1.4 million placement and secured milestone-based Victorian Government funding, accelerating its manufacturing expansion and commercial growth in concussion management technology.

Everest Metals is set to begin toll processing at its Mt Dimer Gold Project in September 2026, backed by strong mining progress and promising high-grade drill results.

Antipa Minerals has upgraded its Minyari Project resource to 3.6 million ounces gold equivalent with a strong increase in indicated resources, while launching a major 41,000m drilling campaign and advancing its Pre-Feasibility Study with encouraging metallurgical and geotechnical results.

Argenica Therapeutics is gearing up for a pivotal late-stage clinical trial of its neuroprotective drug ARG-007 (xaranetide) in acute ischaemic stroke, backed by strong safety assays and solid funding.

Bayan Mining has agreed to sell its Bayan Springs North Project in Nevada to Sun Silver for up to A$800,000, retaining a 1.0% royalty and securing non-dilutive funding to focus on rare earths development.

Anson Resources has secured the initial tranche of a AUD 7.2 million facilitation fee from POSCO, advancing the Green River Lithium Project’s Direct Lithium Extraction demonstration plant in Utah.

Antares Metals (ASX: AM5) has secured approval to begin heritage surveys and drilling at its Quinns VMS project in Western Australia, backed by $237,500 in government co-funding. The company aims to test high-grade extensions of the historic Austin deposit and untested regional prospects, with copper prices rising sharply since the last resource estimate.

Firebird Metals has achieved a key milestone under the ARENA Battery Breakthrough Initiative, unlocking a A$1 million non-dilutive payment and progressing site development for its Australian Demonstration Plant in Perth.

Dimerix has acquired DMX-652, a Phase 2-ready oral drug candidate targeting acute kidney injury, expanding its renal disease portfolio. The acquisition includes patent rights, an FDA-approved trial protocol, and funding to initiate clinical development.

29Metals reported a mixed June quarter with lower copper but higher zinc production at Golden Grove, steady safety metrics, and ongoing development progress including Xantho Extended mining restart and Gossan Valley first ore on track. Capricorn Copper's restart hinges on regulatory approval and a definitive feasibility study due by year-end.

Eminence Minerals has finalised the sale of its Mata da Corda Project in Brazil for USD 2 million, reinforcing its cash position to approximately AUD 5.4 million and sharpening its focus on priority exploration assets.